Skip to main content
Top
Published in: Cancer Microenvironment 1/2016

01-04-2016

SLUG and SOX9 Cooperatively Regulate Tumor Initiating Niche Factors in Breast Cancer

Authors: Hassan Fazilaty, Mossa Gardaneh, Parvin Akbari, Ali Zekri, Babak Behnam

Published in: Cancer Microenvironment | Issue 1/2016

Login to get access

Abstract

Presence of tumor initiating cells and a proper niche is essential for metastatic colonization. SLUG and SOX9 transcription factors play essential roles in induction and maintenance of tumor initiating capacity in breast cancer cells. On the other hand, Tenascin-C and Periostin are crucial factors in metastatic niche that support tumor initiating capability in breast cancer. In this study, regulatory effect of SLUG and SOX9 transcription factors on the expression of Tenascin-C and Periostin was examined. SLUG and SOX9 were overexpressed and knocked-down in MCF7 and MDA-MB-231 cells, respectively. The cells as little and highly invasive breast cancer-derived cells were infected by inducing and shRNA lentivirus constructs. Then, Tenascin-C and Periostin as well as SLUG and SOX9 expression levels were measured in the cells via Real-Time PCR. Simultaneous overexpression of SLUG and SOX9 significantly induced Tenascin-C and Periostin expression. SLUG and SOX9 knock-down also significantly reduced the expression of Tenascin-C and Periostin. In this analysis Periostin showed the most deviation in both up- and down-regulation levels. This regulatory effect might shed light to a crosstalk between factors involved in the tumor initiating capacity and metastatic niche of the breast cancer.
Literature
6.
go back to reference Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions Between Cancer Stem Cells and Their Niche Govern Metastatic Colonization. Nature 481(7379):85–89. doi:10.1038/nature10694 CrossRef Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions Between Cancer Stem Cells and Their Niche Govern Metastatic Colonization. Nature 481(7379):85–89. doi:10.​1038/​nature10694 CrossRef
7.
go back to reference Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J (2011) Breast Cancer Cells Produce Tenascin C as a Metastatic Niche Component to Colonize the Lungs. Nat Med 17(7):867–874. doi:10.1038/nm.2379 CrossRefPubMedPubMedCentral Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massague J (2011) Breast Cancer Cells Produce Tenascin C as a Metastatic Niche Component to Colonize the Lungs. Nat Med 17(7):867–874. doi:10.​1038/​nm.​2379 CrossRefPubMedPubMedCentral
8.
12.
go back to reference Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ (2013) The Perivascular Niche Regulates Breast Tumour Dormancy. Nat Cell Biol 15(7):807–817. doi:10.1038/ncb2767 CrossRefPubMedPubMedCentral Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ (2013) The Perivascular Niche Regulates Breast Tumour Dormancy. Nat Cell Biol 15(7):807–817. doi:10.​1038/​ncb2767 CrossRefPubMedPubMedCentral
Metadata
Title
SLUG and SOX9 Cooperatively Regulate Tumor Initiating Niche Factors in Breast Cancer
Authors
Hassan Fazilaty
Mossa Gardaneh
Parvin Akbari
Ali Zekri
Babak Behnam
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2016
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-015-0176-8

Other articles of this Issue 1/2016

Cancer Microenvironment 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine